AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$54.22
neg -0.26
-0.48%
Today's Range: 54.08 - 54.56 | ABBV Avg Daily Volume: 6,587,300
Last Update: 07/24/14 - 10:11 AM EDT
Volume: 1,916,487
YTD Performance: 3.16%
Open: $54.22
Previous Close: $54.48
52 Week Range: $42.25 - $58.27
Oustanding Shares: 1,590,066,459
Market Cap: 85,307,065,525
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 1 1 0
Hold 3 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.86 2.05 2.05 2.11
Latest Dividend: 0.42
Latest Dividend Yield: 3.11%
Dividend Ex-Date: 07/11/14
Price Earnings Ratio: 21.03
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
21.03 11.60 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.66% 22.95% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
EBITDA 6.97B
Revenue 18.38B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $0.76 $0.77 $3.15 $3.79
Number of Analysts 3 2 7 6
High Estimate $0.77 $0.78 $3.20 $3.93
Low Estimate $0.76 $0.76 $3.08 $3.49
Prior Year $0.82 $0.82 $3.14 $3.15
Growth Rate (Year over Year) -6.91% -6.10% 0.18% 20.38%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Jul 23, 2014 | 7:41 AM EDT
ABBV was placed on the US 1 list, according to Bank of America/Merrill Lynch said. Estimates also increased, given higher expected Hepa...

This Morning's Market Setup Real Money Pro($)

Where it began.
Bullish
May 07, 2014 | 8:12 AM EDT
ABBV was upgraded from Equal-weight to Overweight, Morgan Stanley said. $60 price target. Company has an attractive pipeline and can ge...
The market wants companies that are taking share with minimal spending.
Investors may be worried about Sovaldi's price.
Its potent hepatitis C treatment is not a boon for shareholders.

Dividend D-Day Coming Real Money Pro($)

The goal is always simply to get out where we got in.
Bearish
Mar 19, 2014 | 7:33 AM EDT
ABBV cut its number, Jefferies said. Competitive data in Hep C, pay for delay litigation re Androgel. $60 price target. 
Bearish
Dec 19, 2013 | 7:48 AM EST
ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $57 price target. 
Bullish
Dec 03, 2013 | 8:11 AM EST
ABBV was placed on the Conviction Buy list, according to Goldman Sachs. Company has an attractive pipeline, with multiple potential cat...

Columnist Conversations

A raft of good earnings cannot push the VIX down today. What ever is driving volatility lately it is not comi...
USA New Home Sales for Jun 406.0K vs 479.0K Est; Prior 504.0K...New Home Sales (MoM) for Jun -8.10% vs -5.30% ...
Gold typically moves higher in the month of August due to seasonal demand pressures. Nonetheless, the shruggi...
If history is any guide, then shorting F5 Networks (FFIV) and buying Qualcomm (QCOM) is the trade here. FFIV h...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.